arrow
M

Montse Sánchez-Céspedes

Josep Carreras Leukaemia Research Institute
H指数:62
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

2025年肺癌基础与转化研究进展——聚焦NSCLC的概述与展望

2025-06-030
PRE
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy

DSTYK抑制增强了非小细胞肺癌对紫杉烷类化疗的敏感性

2024-11-010
PRE
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

用免疫疗法治疗的具有KRAS突变的转移性肺癌患者队列的特征: 根据KRAS G12C与non-G12C的差异

2023-10-174
OAAI
MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
2023-04-0111
OAAI
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
2021-09-2913
OA
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
2021-07-1430
OAAI
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
2021-01-0626
OAAI
The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells

MNT转录因子自动调节其表达并支持MYC相关因子X (MAX) 缺陷细胞的增殖

2020-02-0110
OAAI
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
2020-02-0133
OAAI
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib
2019-10-0154
OAAI
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

非小细胞肺癌anti-PD-1治疗反应的表观遗传学预测: 一项多中心回顾性分析

2018-10-01168
OAAI